Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Other Accumulated Expenses (2021 - 2025)

Valion Bio has reported Other Accumulated Expenses over the past 5 years, most recently at $376000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 184.85% year-over-year to $376000.0; the TTM value through Dec 2025 reached $376000.0, up 184.85%, while the annual FY2025 figure was $376000.0, 184.85% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $376000.0 at Valion Bio, up from $173000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $587000.0 in Q2 2025 and troughed at $132000.0 in Q4 2024.
  • A 5-year average of $285294.1 and a median of $267000.0 in 2021 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 73.33% in 2024 and later surged 304.83% in 2025.
  • Year by year, Other Accumulated Expenses stood at $267000.0 in 2021, then soared by 46.82% to $392000.0 in 2022, then increased by 26.28% to $495000.0 in 2023, then plummeted by 73.33% to $132000.0 in 2024, then soared by 184.85% to $376000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for TIVC at $376000.0 in Q4 2025, $173000.0 in Q3 2025, and $587000.0 in Q2 2025.